Clinical trial · Interventional
Study of DC-CIK to Treat Colorectal Cancer
Phase Ⅱ Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Stage Ⅲ Colorectal Cancer
NCT01839539CI-TRIAL-00010133unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy of dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dendritic and cytokine-induced killer cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- B
- description
- After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will only regularly follow up.
- type
- EXPERIMENTAL
- label
- A
- description
- After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will receive 2-3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) treatment (every 4 weeks).
- interventionNames
- Biological: dendritic and cytokine-induced killer cells
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- 5 years
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female patients ≥ 18 years of age; 2. CRC with histological diagnose, and had received neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy and got complete response (CR) with imaging; 3. Patients who have a life expectancy of at least 3 months; 4. Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1; 5. The bone marrow functioned normally (WBC \> 4.0×109/L, Hb \> 120 g/L, PLT \> 100×109/L); 6. The ECG results were normal, and the liver and kidney were functional. Exclusion Criteria: 1. Patients who had distant metastases; 2. Patients with uncontrolled infection; underlying disease that was severe or life-threatening; 3. Patients who were pregnant or lactating; 4. ECOG perform status ≥ 2; 5. Patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.